European VCs may be better prepared for a downturn than their US peers Posted on 11.07.202218.07.2022 by Oliver Kahl
BioNTechs second act: can it transform the fight against cancer? Posted on 15.06.202230.06.2022 by Oliver Kahl
The unintended consequences of Vestager´s tougher take of „killer acquisitions“. Posted on 14.10.202129.06.2022 by Oliver Kahl
